Ethics and Disclosure Sample Clauses

Ethics and Disclosure. I affirm the Author Representations noted below, and confirm that I have reviewed and complied with the relevant Instructions to Authors, Ethics in Publishing policy, and Conflicts of Interest disclosure. Please note that some journals may require that all co-authors sign and submit Conflicts of Interest disclosure forms. I am also aware of the publisher’s policies with respect to retractions and withdrawal. I am also aware of the publisher’s policies with respect to retractions and withdrawal and the journal home page. • The article I have submitted to the journal for review is original, has been written by the stated authors and has not been published elsewhere. • The article is not currently being considered for publication by any other journal and will not be submitted for such review while under review by this journal. • The article contains no libelous or other unlawful statements and does not contain any materials that violate any personal or proprietary rights of any other person or entity. • I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in my article. • If I am using any personal details or images of patients or research subjects, I have obtained written permission or consent from the patient (or, where applicable, the next of kin). • If the article was prepared jointly with other authors, I have informed the co-author(s) of the terms of this publishing agreement and that I am signing on their behalf as their agent, and I am authorized to do so. DEFINITIONS Author’s version of the manuscript of an article that has been accepted for publication and which may include any author-incorporated changes suggested through the processes of submission processing, peer review, and editor-author communications. AAMs should not include other publisher value added contributions such as copy-editing, formatting and (if relevant) pagination, and should include the Appropriate Bibliographic Citation and a link to the final publication. Authors posting Accepted Author Manuscript online should later add a citation for the Published Journal Article indicating that the Article was subsequently published, and may mention the journal title provided they add the following text at the beginning of the document:
View SourceView Similar (6)
Ethics and Disclosure. I affirm the Author Warranties noted below, and confirm that I have reviewed and complied with the relevant Instructions to Authors, the Ethics in Publishing policy, and Declarations of Interest disclosure. For further information see the IFAC web site, ▇▇▇▇▇://▇▇▇.▇▇▇▇-▇▇▇▇▇▇▇.▇▇▇/.
View SourceView Similar (2)
Ethics and Disclosure. I affirm the Author Representations noted below, and confirm that I have reviewed and complied with the relevant Instructions to Authors, SSWR Policy on Publication Ethics and Publication Malpractice Statement Ethics. I am also aware of the publisher's policies with respect to retractions and withdrawal
View SourceView Similar (2)
Ethics and Disclosure. If this Agreement includes services for attempting to influence government action, or any other form of lobbying, then the following are required. Please also see Section 5 of the Agreement Check If Applicable or indicate “N/A”: N/A Federal Lobbying: Contractor will timely provide F▇▇▇▇▇ M▇▇ the amount of fees and services which are reportable as lobby activities under the Federal Lobby Disclosure Act. N/A State/Local Lobbying: Contractor will not engage in any state or local lobbying requiring registration or disclosure by Contractor or F▇▇▇▇▇ M▇▇ under a state or local lobby law without such prior approval in a letter signed by Fannie Mae’s Business Point of Contact.
View Source
Ethics and Disclosure. If this Agreement includes services for attempting to influence government action, or any other form of lobbying, then the following are required. Please also see Section 5 of the Agreement Check If Applicable or indicate “N/A”: N/A Federal Lobbying: Contractor will timely provide ▇▇▇▇▇▇ ▇▇▇ the amount of fees and services which are reportable as lobby activities under the Federal Lobby Disclosure Act. N/A State/Local Lobbying: Contractor will not engage in any state or local lobbying requiring registration or disclosure by Contractor or ▇▇▇▇▇▇ Mae under a state or local lobby law without such prior approval in a letter signed by ▇▇▇▇▇▇ Mae’s Business Point of Contact.
View Source
Ethics and Disclosure. 3.1 The Grant Recipient shall ensure that all use of Grant funds complies with the MedTech Europe Code of Ethical Business Practice and all applicable laws and legal regulations and industry codes of conduct. Particularly, where the Grant is provided to support Healthcare Professionals’ attendance at Third Party Organised Educational Events, the Grant Recipient shall ensure that the Grant is used in accordance with Chapter 1: General Criteria for Events, of MedTech Europe Code of Ethical Business Practice, including, but not limited to, the following principles: (a) Program akce: má přímo souviset s odborností nebo lékařskou praxí zdravotnického pracovníka účastnícího se akce nebo být natolik relevantní, aby jeho účast na akci opodstatnil; (a) The Event Programme: it should directly relate to the specialty and/or medical practice of the Healthcare Professional attending the event, or be sufficiently relevant to justify the Healthcare Professional’s attendance; (b) Lokace a místo konání akce: nemá být hlavní motivací Projektu; (b) Event Location and Venue: it should not become the main attraction of the Programme;
View Source
Ethics and Disclosure. (a) F▇▇▇▇▇ M▇▇ adheres to the highest standards of ethical conduct and disclosure in its interaction with government. F▇▇▇▇▇ M▇▇ requires Contractor to comply with all applicable lobby, gift, conflict of interest, ethics, and campaign contribution statutes, laws, and regulations and to avoid any appearance of impropriety. Contractor understands that failure to comply with such laws, and with the specific provisions of this section, may result in immediate termination of this Agreement, delayed payment by F▇▇▇▇▇ M▇▇ or other sanctions. (b) Contractor agrees to comply with the following specific requirements in regard to direct or indirect lobbying of any government entity. (1) The Statement of Work must indicate if Contractor expects to lobby, register as a lobbyist, or engage in lobby activity on behalf of F▇▇▇▇▇ M▇▇. If Contractor expects to change its status in this regard, Contractor must provide an amended Statement of Work or Order Form to the F▇▇▇▇▇ M▇▇ Business Point of Contact reflecting that change in status prior to engaging in lobbying on behalf of F▇▇▇▇▇ M▇▇. (2) Contractor shall respond in a timely manner to requests for information from Fannie Mae’s, Business Point of Contact as identified in accordance with Section 2, for the purpose of ensuring Fannie Mae’s compliance with applicable federal, state and local law, as well as conflict of interest laws, gift laws, tax laws, and laws pertaining to political contributions. F▇▇▇▇▇ M▇▇ will similarly respond to any such requests from Contractor. (3) In regard to federal lobbying activity, Contractor shall provide to Fannie Mae’s Business Point of Contact an accounting of any and all fees and services to be disclosed by F▇▇▇▇▇ M▇▇ under the Federal Lobby Disclosure Act on each monthly invoice, or in another mutually agreed upon manner in writing. (4) In regard to any state or local lobbying, Contractor shall obtain prior written approval from Fannie Mae’s Business Point of Contact prior to engaging in state or local lobbying on behalf of F▇▇▇▇▇ M▇▇, and further provide any information requested by F▇▇▇▇▇ M▇▇ in questionnaires provided for the purpose of full and adequate disclosure of lobby activity. (5) Contractor shall, provide copies of any public filing disclosing the lobbying activities of Contractor on behalf of F▇▇▇▇▇ M▇▇. Any such document requiring an authorized signature by a representative of F▇▇▇▇▇ M▇▇ shall be provided to Fannie Mae’s Business Point Contact for signature. (6) Contracto...
View Source
Ethics and Disclosure. I affirm the Author Representations noted below and confirm that I have reviewed and complied with the relevant Instructions to Authors, Ethics in Publishing policy, Declarations of Interest disclosure, and information for authors from countries affected by sanctions. Please note that some journals
View Source

Related to Ethics and Disclosure

  • Use and Disclosure All Confidential Information of a party will be held in confidence by the other party with at least the same degree of care as such party protects its own confidential or proprietary information of like kind and import, but not less than a reasonable degree of care. Neither party will disclose in any manner Confidential Information of the other party in any form to any person or entity without the other party’s prior consent. However, each party may disclose relevant aspects of the other party’s Confidential Information to its officers, affiliates, agents, subcontractors and employees to the extent reasonably necessary to perform its duties and obligations under this Agreement and such disclosure is not prohibited by applicable law. Without limiting the foregoing, each party will implement physical and other security measures and controls designed to protect (a) the security and confidentiality of Confidential Information; (b) against any threats or hazards to the security and integrity of Confidential Information; and (c) against any unauthorized access to or use of Confidential Information. To the extent that a party delegates any duties and responsibilities under this Agreement to an agent or other subcontractor, the party ensures that such agent and subcontractor are contractually bound to confidentiality terms consistent with the terms of this Section 11.

  • Publicity and Disclosures No press releases or public disclosure, either written or oral, of the transactions contemplated by this Agreement, shall be made by a party to this Agreement without the prior knowledge and written consent of Buyer and the Company.

  • Use and Disclosure of PHI Business Associate is limited to the following permitted and required uses or disclosures of PHI: a. Duty to Protect PHI. Business Associate shall protect PHI from, and shall use appropriate safeguards, and comply with Subpart C of 45 CFR Part 164 (Security Standards for the Protection of Electronic Protected Health Information) with respect to EPHI, to prevent the unauthorized Use or disclosure of PHI other than as provided for in this Contract or as required by law, for as long as the PHI is within its possession and control, even after the termination or expiration of this Contract.

  • Confidentiality and Disclosure (a) The Agent and the Borrower agree to keep the Cost of Funding of each Lender (and, in the case of the Agent, each Reference Bank Quotation) confidential and not to disclose it to anyone, save to the extent permitted by paragraphs (b), (c) and (d) below. (b) The Agent may disclose: (i) the Cost of Funding of each Lender (but not, for the avoidance of doubt, any Reference Bank Quotation) to the Borrower pursuant to Clause 5.4; and (ii) the Cost of Funding of any Lender or any Reference Bank Quotation to any person appointed by it to provide administration services in respect of one or more of the Finance Documents to the extent necessary to enable such service provider to provide those services if the service provider to whom that information is to be given has entered into a confidentiality agreement in such form of confidentiality undertaking agreed between the Agent and the relevant Lender or Reference Bank, as the case may be. (c) The Agent may disclose the Cost of Funding of any Lender or any Reference Bank Quotation, and the Borrower may disclose the Cost of Funding of any Lender, to: (i) any of its affiliates and any of its or their officers, directors, employees, professional advisers, auditors, partners and representatives, if any person to whom the Cost of Funding of that Lender or Reference Bank Quotation is to be given pursuant to this sub-paragraph (i) is informed in writing of its confidential nature and that it may be price sensitive information except that there shall be no such requirement to so inform if the recipient is subject to professional obligations to maintain the confidentiality of the Cost of Funding of that Lender or Reference Bank Quotation or is otherwise bound by requirements of confidentiality in relation to it; (ii) any person to whom information is required or requested to be disclosed by any court of competent jurisdiction or any governmental, banking, taxation or other regulatory authority or similar body, the rules of any relevant stock exchange or pursuant to any applicable law or regulation if the person to whom the Cost of Funding of that Lender or Reference Bank Quotation is to be given is informed in writing of its confidential nature and that it may be price sensitive information except that there shall be no requirement to so inform if, in the opinion of the Agent or the Borrower, as the case may be, it is not practicable to do so in the circumstances; (iii) any person to whom information is required to be disclosed in connection with, and for the purposes of, any litigation, arbitration, administrative or other investigations, proceedings or disputes if the person to whom the Cost of Funding of that Lender or Reference Bank Quotation is to be given is informed in writing of its confidential nature and that it may be price sensitive information except that there shall be no requirement to so inform if, in the opinion of the Agent or the Borrower, as the case may be, it is not practicable to do so in the circumstances; and (iv) any person with the consent of the relevant Lender or Reference Bank, as the case may be. (d) The Agent’s obligations in this Clause 31 relating to Reference Bank Quotations are without prejudice to its obligations to make notifications under Clause 5.4 provided that (other than pursuant to sub-paragraph (i) of paragraph (b) above) the Agent shall not include the details of any individual Reference Bank Quotation as part of any such notification.

  • Public Statements and Disclosure The initial press release concerning this Agreement and the Merger will be a joint press release reasonably acceptable to the Company and Parent and will be issued promptly following the execution and delivery of this Agreement. Thereafter, unless the Company Special Committee has made a Company Recommendation Change, the Company and its Representatives, on the one hand, and Parent and Merger Sub and their respective Representatives, on the other hand, will consult with the other Parties before (a) participating in any media interviews; (b) engaging in any meetings or calls with analysts, institutional investors or other similar Persons; or (c) providing any statements that are public or are reasonably likely to become public, in each case to the extent relating to this Agreement or the Merger and neither party shall issue any press release or make any public announcement or statement without the consent of the other party, which shall not be unreasonably withheld, conditioned or delayed; provided, that to the extent such release or announcement is required by applicable Law or any listing agreement with or rule of any national securities exchange or association upon which the securities of the Company are listed, the party required to make the release, announcement or statement shall use reasonable best efforts to consult with the other Party about, and allow the other Party reasonable time (taking into account the circumstances) to comment on, such release, announcement or statement in advance of such issuance. Notwithstanding the foregoing, neither Parent nor the Company will be obligated to engage in such consultation with respect to communications that are (i) principally directed to its employees, drivers, suppliers, customers, partners or vendors so long as such communications are consistent with prior communications previously agreed to by Parent and the Company and do not add additional material information not included in such previous communication (in which case such communications may be made consistent with such plan); (ii) related to a Superior Proposal or Company Recommendation Change or, in each case, any action taken pursuant thereto; (iii) with respect to any dispute or Legal Proceeding solely among the Parties or their respective Affiliates related to this Agreement or the Transaction Documents; or (iv) substantively consistent with previous public disclosures made by the Parties in compliance with this Section 6.13 and which do not add additional material information not included in such previous disclosure. Parent will not be obligated to engage in such consultation with respect to communications that are principally directed to its existing or prospective equity holders and investors of Parent or its Affiliates, so long as such communications are consistent with prior communications previously agreed to by Parent and the Company and do not add additional material information not included in such previous communication.